Toronto, Ontario–(Newsfile Corp. – January 4, 2022) – Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, announced that management, the Board of Directors (“the Board”) and key shareholders (the “Lock-up Shareholders”) have voluntarily entered into a Lock…


Previous articlePT281 – Oliver Grundmann, Ph.D. – A Thorough Exploration of Kratom
Next articleThe McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines